Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19
Senhwa Biosciences, a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and […]
ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
Shionogi today announced that two late-breaking poster presentations featuring new results from the Phase 3 […]
PharmaJet Announces Clinical Results from Scancell’s COVID-19 DNA Vaccine Study Exclusively Administered with Needle-free Precision Delivery Systems
PharmaJet, a company engineering precision delivery systems that may overcome the challenges of nucleic acid […]
COVID-19 Rapid Antigen Self-Test, COVI-Go, receives FDA Emergency Use Authorization for Home Use
Mologic, the US subsidiary of Global Access Diagnostics (GADx), a leading developer of lateral flow […]
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
Novavax, a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, […]
Antiparasitic Drug Could Prevent Coronavirus Lung Damage
A common antiparasitic drug could block lung damage in people with coronavirus, according to new […]
GSK to support manufacture of Novavax' COVID-19 vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the […]
Moderna 100 Millionth Dose Shipment of COVID-19 Vaccine to U.S.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
AZD1222 US Phase III Primary Analysis Confirms Vaccine Safety and Efficacy
76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more